Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lianbio ADR (LIAN)

Lianbio ADR (LIAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,472
  • Shares Outstanding, K 108,063
  • Annual Sales, $ 0 K
  • Annual Income, $ -110,290 K
  • 60-Month Beta 0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.14
Trade LIAN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.81
  • Most Recent Earnings $-0.22 on 11/13/23
  • Latest Earnings Date 03/25/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +587,747.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2712 +17.63%
on 03/15/24
4.9900 -93.61%
on 03/14/24
-4.4510 (-93.31%)
since 02/16/24
3-Month
0.2712 +17.63%
on 03/15/24
4.9900 -93.61%
on 03/14/24
-3.7910 (-92.24%)
since 12/18/23
52-Week
0.2712 +17.63%
on 03/15/24
4.9900 -93.61%
on 03/14/24
-1.4210 (-81.67%)
since 03/17/23

Most Recent Stories

More News
Why LianBio Stock Is Shooting Through the Roof This Week

LianBio stock is seeing explosive gains, and it's one of this week's biggest winners.

LIAN : 0.3190 (-8.28%)
Why LianBio Stock Is Skyrocketing Today

Investors are loving LianBio's new deal with Bristol Myers Squibb.

LIAN : 0.3190 (-8.28%)
BMY : 44.54 (-0.45%)
Novo Nordisk (NVO) Q4 Earnings Beat Estimates, Revenues Miss

Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

SNY : 49.07 (+0.78%)
NVO : 129.13 (+0.37%)
CABA : 11.39 (-6.79%)
LIAN : 0.3190 (-8.28%)
Horizon (HZNP) Dazodalibep Meets Goal in Sjogren's Syndrome Study

Horizon Therapeutics (HZNP) announces that a phase II Sjogren's syndrome study of its candidate, dazodalibep, meets the primary endpoint for the second population.

AMGN : 313.61 (+0.24%)
HZNP : 116.30 (+0.04%)
CELU : 3.05 (unch)
LIAN : 0.3190 (-8.28%)
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China

As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments....

PFE : 28.01 (-0.60%)
AMRN : 0.8615 (-2.10%)
KMDA : 5.57 (+0.14%)
LIAN : 0.3190 (-8.28%)
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Regulatory News:

NBTX : 6.89 (+3.30%)
LIAN : 0.3190 (-8.28%)
LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

• Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy Chinese volunteers, expected to support registration of...

LIAN : 0.3190 (-8.28%)
LianBio to Participate in June Investor Events

SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative...

LIAN : 0.3190 (-8.28%)
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update

LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic...

LIAN : 0.3190 (-8.28%)
U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

LianBio to Continue Development of Camzyos in China and Other Asian Territories...

LIAN : 0.3190 (-8.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

LianBio is a cross-border biotechnology company dedicated to bringing medicines to patients principally in China and other major Asian markets. LianBio is based in SHANGHAI, China.

See More

Key Turning Points

3rd Resistance Point 0.4241
2nd Resistance Point 0.3869
1st Resistance Point 0.3530
Last Price 0.3190
1st Support Level 0.2819
2nd Support Level 0.2447
3rd Support Level 0.2108

See More

52-Week High 4.9900
Fibonacci 61.8% 3.1874
Fibonacci 50% 2.6306
Fibonacci 38.2% 2.0738
Last Price 0.3190
52-Week Low 0.2712

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar